Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Kerendia
Finerenone is a nonsteroidal mineralocorticoid receptor antagonist (MRA) indicated to reduce the risk of kidney failure, cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D). It selectively blocks the binding of aldosterone to the mineralocorticoid receptor, thereby reducing the harmful effects of aldosterone on the kidneys and cardiovascular system. It is classified as a potassium-sparing diuretic.
Finerenone is used to reduce the risk of kidney failure, cardiovascular death, heart attack, stroke, and heart failure hospitalization in adults with chronic kidney disease associated with type 2 diabetes.
Outcome:
Hyperkalemia
Mechanism:
Additive potassium retention
Outcome:
Reduced renal function
Mechanism:
Inhibition of prostaglandin synthesis
Outcome:
Decreased finerenone levels
Mechanism:
CYP3A4 induction
Most likely new formulation: Combination therapy with SGLT2 inhibitor (2025, 70% confidence)
Based on current clinical trial data and market trends, there is a high (85%) likelihood of continued approval and expanded indications for finerenone in related cardiovascular and renal conditions.
Mineralocorticoid Receptor Antagonist, Potassium-Sparing Diuretic
Pyridazinone derivative